The harmful health effects of recreational ecstasy: a systematic review of observational evidence.
暂无分享,去创建一个
R Garside | J. Elston | R. Garside | G. Rogers | M. Somerville | A. Zawada | R. Taylor | M Somerville | G. Rogers | C. Roome | P. Younger | J Elston | G Rogers | C Roome | R Taylor | P Younger | A Zawada
[1] P. Croft,et al. Quality assessment of observational studies is not commonplace in systematic reviews. , 2006, Journal of clinical epidemiology.
[2] S. Gabriel,et al. Systematic Review of the Literature , 2021, Adherence to Antiretroviral Therapy among Perinatal Women in Guyana.
[3] R. B. Smith,et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.
[4] Sarah C E Riley,et al. Patterns, Trends, and Meanings of Drug Use by Dance-drug Users in Edinburgh, Scotland , 2004 .
[5] J. Ferlay,et al. Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.
[6] G. Gerra,et al. Hypothalamic–pituitary–adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine (‘ecstasy’) use history: correlation with dopamine receptor sensitivity , 2003, Psychiatry Research.
[7] A. Partin,et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.
[8] P. Nelson,et al. New nomenclature for the human tissue kallikrein gene family. , 2000, Clinical chemistry.
[9] Peter H Gann,et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.
[10] F. Schifano,et al. Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994–2003) , 2006, Journal of psychopharmacology.
[11] B. Kessel. Hyponatraemia after ingestion of “ectasy” , 1994 .
[12] H. Rosenberg,et al. A review of the acute subjective effects of MDMA/ecstasy. , 2006, Addiction.
[13] J. Fisk,et al. The nature of ecstasy-group related deficits in associative learning , 2005, Psychopharmacology.
[14] J. Sills,et al. Cerebral oedema after ingestion of MDMA (“ecstasy”) and unrestricted intake of water , 1996, BMJ.
[15] H. Nordgren,et al. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival , 2004, Urological Research.
[16] K. Olson,et al. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. , 2005, The Journal of emergency medicine.
[17] E. Lehmann,et al. Delayed severe rhabdomyolysis after taking 'ecstasy'. , 1995, Postgraduate medical journal.
[18] J. Fisk,et al. Verbal working memory deficits in current and previous users of MDMA , 2004, Human psychopharmacology.
[19] H. Wittchen,et al. Mental disorders in ecstasy users: a prospective-longitudinal investigation. , 2002, Drug and alcohol dependence.
[20] M. Kattan,et al. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Arieff. Management of hyponatraemia. , 1993, BMJ.
[22] Michelle N Lafrance. A Bitter Pill , 2007, Journal of health psychology.
[23] D. Weckermann,et al. Prostate Cancer Relapse after Therapy with Curative Intention: A Diagnostic and Therapeutic Dilemma , 2005, Oncology Research and Treatment.
[24] B. Schmand,et al. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users , 2006, Journal of psychopharmacology.
[25] R. Schwartz,et al. MDMA (ecstasy) and the rave: a review. , 1997, Pediatrics.
[26] W. Lambert,et al. Postmortem distribution of 3,4-methylenedioxy-N,N-dimethyl-amphetamine (MDDM or MDDA) in a fatal MDMA overdose , 2007, International Journal of Legal Medicine.
[27] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[28] R. de Silva,et al. ‘Ecstasy’ and Intracerebral Haemorrhage , 1992, Scottish medical journal.
[29] T. Therneau,et al. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. , 1990, Archives of surgery.
[30] B. Sahakian,et al. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users , 2002, Psychopharmacology.
[31] C. C. Duncan,et al. Analysis of the elements of attention: A neuropsychological approach , 1991, Neuropsychology Review.
[32] R. Zietse,et al. Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. , 2005, QJM : monthly journal of the Association of Physicians.
[33] John P A Ioannidis,et al. Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.
[34] A. Freemont,et al. Ecstasy, 3–4 Methylenedioxymethamphetamine (MDMA), a Fatality Associated with Coagulopathy and Hyperthermia , 1991, Journal of the Royal Society of Medicine.
[35] M. Gill,et al. MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6 , 1998, Addiction biology.
[36] J. Collins,et al. A network biology approach to prostate cancer , 2007, Molecular systems biology.
[37] D G Altman,et al. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines , 2004, British Journal of Cancer.
[38] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[39] J. Staffurth,et al. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. , 2007, The Lancet. Oncology.
[40] M. Tancer,et al. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans , 2005, Psychopharmacology.
[41] T. Newton,et al. MDMA use and neurocognition: a meta-analytic review , 2006, Psychopharmacology.
[42] Douglas G Altman,et al. Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.
[43] E. Wilkinson. Cancer Research UK , 2002 .
[44] E. Bergstralh,et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. , 2001, The Journal of urology.
[45] W. van den Brink,et al. How to find future ecstasy-users: targeted and snowball sampling in an ethically sensitive context. , 2007, Addictive behaviors.
[46] J. Fisk,et al. Visuo‐spatial working memory deficits in current and former users of MDMA (‘ecstasy’) , 2005, Human psychopharmacology.
[47] H. Kalant,et al. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[48] J. Oesterling,et al. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. , 1995, The Journal of urology.
[49] G. Guyatt,et al. Users' guides to the medical literature. , 1993, JAMA.
[50] M. Colado,et al. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (`ecstasy') , 1998, Neuropharmacology.
[51] N Cascinelli,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] J. Henry,et al. Fatal interaction between ritonavir and MDMA , 1998, The Lancet.
[53] D. Hilton‐Jones,et al. Death after ecstasy ingestion: neuropathological findings. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[54] S. Ricci,et al. Suramin in combination with weekly epirubicin for patients with advanced hormone‐refractory prostate carcinoma , 1999, Cancer.
[55] M. Colado,et al. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. , 2004, European journal of pharmacology.
[56] C. Magee,et al. Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female. , 1998, Irish medical journal.
[57] J. Fisk,et al. Everyday memory deficits in ecstasy-polydrug users , 2007, Journal of psychopharmacology.
[58] B. Conley,et al. Detection of Prostate Cancer and Predicting Progression , 2004, Clinical Cancer Research.
[59] F. Hamdy,et al. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. , 2006, The Journal of urology.
[60] J A Henry,et al. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. , 2006, British journal of anaesthesia.
[61] M. Hickman,et al. London audit of drug-related overdose deaths: characteristics and typology, and implications for prevention and monitoring. , 2007, Addiction.
[62] E. Gouzoulis-Mayfrank,et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) , 2000, Journal of neurology, neurosurgery, and psychiatry.
[63] Jacob Cohen. Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.
[64] M. Kattan,et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] O. Spreen,et al. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary , 1991 .
[66] Douglas G. Altman,et al. Methodological challenges in the evaluation of prognostic factors in breast cancer. , 1998 .
[67] M. Anscher,et al. Multivariate analysis of factors predicting local relapse after radical prostatectomy--possible indications for postoperative radiotherapy. , 1991, International journal of radiation oncology, biology, physics.
[68] J. Kench,et al. Lower levels of nuclear β‐catenin predict for a poorer prognosis in localized prostate cancer , 2005, International journal of cancer.
[69] A. McEvoy,et al. Intracerebral haemorrhage and drug abuse in young adults. , 2000, British journal of neurosurgery.
[70] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[71] D. Groome,et al. Cognitive Performance in Light Current Users and Ex-Users of Ecstasy (MDMA) and Controls , 2007, The American journal of drug and alcohol abuse.
[72] F. Critz,et al. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. , 2004, The Journal of urology.
[73] Rodney J. Croft,et al. The relative contributions of ecstasy and cannabis to cognitive impairment , 2001, Psychopharmacology.
[74] Frank Davidoff,et al. Predicting Clinical States in Individual Patients , 1996, Annals of Internal Medicine.
[75] F. Gilliland,et al. Effects of misattribution in assigning cause of death on prostate cancer mortality rates. , 2003, Annals of epidemiology.
[76] N. Vassiliadis,et al. Amphetamine derivative related deaths in northern Greece. , 2002, Forensic science international.
[77] Daniel B. Mark,et al. TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .
[78] A. Forsyth. Distorted? a quantitative exploration of drug fatality reports in the popular press , 2001 .
[79] Henrik Grönberg,et al. Prostate cancer epidemiology , 2003, The Lancet.
[80] T M Luider,et al. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. , 2005, European urology.
[81] M. Wheaton,et al. THE EFFECTS OF METHYLENEDIOXYMETHAMPHETAMINE (MDMA, “ECSTASY”) ON MONOAMINERGIC NEUROTRANSMISSION IN THE CENTRAL NERVOUS SYSTEM , 1996, Progress in Neurobiology.
[82] D. Carter. TNM Classification of Malignant Tumors , 1998 .
[83] N L Geller,et al. The analysis of multiple endpoints in clinical trials. , 1987, Biometrics.
[84] A. Parrott. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity , 2004, Psychopharmacology.
[85] A. Bechara,et al. Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls , 2006, Journal of psychopharmacology.
[86] M. Davies,et al. Ecstasy induced acute myocardial infarction , 2001, Heart.
[87] R. Byard,et al. Death and paramethoxyamphetamine — an evolving problem , 2002, Medical Journal of Australia.
[88] S. Satchell,et al. Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. , 1994, British journal of hospital medicine.
[89] H. Tanke,et al. Identification of Genetic Markers for Prostatic Cancer Progression , 2000, Laboratory Investigation.
[90] M. Shen,et al. Molecular genetics of prostate cancer. , 2000, Genes & development.
[91] E. Bergstralh,et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? , 2001, The Journal of urology.
[92] D. Altman,et al. Where Next for Evidence Synthesis of Prognostic Marker Studies? Improving the Quality and Reporting of Primary Studies to Facilitate Clinically Relevant Evidence-Based Results , 2007 .
[93] D. Chan,et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.
[94] P. Rothwell,et al. Cerebral venous sinus thrombosis induced by 'ecstasy'. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[95] Jones,et al. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications , 1999, Alimentary pharmacology & therapeutics.
[96] J. M. Quiroga,et al. Hyperkalemia in fatal MDMA ('ecstasy') toxicity. , 2004, International journal of cardiology.
[97] K. Woźniak,et al. Fatality due to the use of a designer drug MDMA (Ecstasy). , 2007, Legal medicine.
[98] F. Schifano,et al. Personality dimensions and psychopathological profiles of Ecstasy users , 2001, Human psychopharmacology.
[99] J. Coakley,et al. Exertional heat stroke induced by amphetamine analogues , 1993, Anaesthesia.
[100] P. Heikkilä,et al. Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations , 2006, Journal of Cancer Research and Clinical Oncology.
[101] P. Albertsen. PSA and the conservative treatment of early prostate cancer. , 2006, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[102] R. Evans,et al. Intracranial haemorrhage associated with ingestion of 'ecstasy'. , 1993, Archives of emergency medicine.
[103] N. Ramsey,et al. The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance , 2005, International journal of methods in psychiatric research.
[104] Pataravit Rukskul. Ecstasy (MDMA) ingestion related with severe hyponatremia in patients with mild head injury. , 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[105] M. Blute,et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. , 2005, The Journal of urology.
[106] Rupert G. Miller,et al. Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.
[107] J. V. van Gerven,et al. Cognitive performance and serotonergic function in users of ecstasy , 2000, Psychopharmacology.
[108] P. Humphrey,et al. The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. , 2001, American journal of clinical pathology.
[109] D. Wright,et al. Shedding new light on the "safe" club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. , 2004, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[110] Michael W Kattan,et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] G. Nahler. disease free survival (DFS) , 2009 .
[112] Richard D Riley,et al. Bivariate random-effects meta-analysis and the estimation of between-study correlation , 2007, BMC Medical Research Methodology.
[113] L. Bubendorf. High–Throughput Microarray Technologies: From Genomics to Clinics , 2001, European Urology.
[114] A. Bond,et al. Ecstasy (MDMA) does not have long-term effects on aggressive interpretative bias: a study comparing current and ex-ecstasy users with polydrug and drug-naive controls. , 2007, Experimental and clinical psychopharmacology.
[115] M. Liechti,et al. Acute medical problems due to Ecstasy use. Case-series of emergency department visits. , 2005, Swiss medical weekly.
[116] T. Peters,et al. A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). , 2006, Contemporary clinical trials.
[117] Ting-I Lai,et al. Methylene 3, 4 dioxymethamphetamine-induced acute myocardial infarction. , 2003, Annals of emergency medicine.
[118] P C Lambert,et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future , 2003, British Journal of Cancer.
[119] H. Meltzer,et al. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. , 1988, The Journal of pharmacology and experimental therapeutics.
[120] A. Parrott,et al. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug , 2001, Journal of psychopharmacology.
[121] W. Sakr,et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy , 2005, Cancer.
[122] F. Jessen,et al. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction , 2006, Journal of psychopharmacology.
[123] D. Grignon,et al. Long-term survival after radiotherapy alone: radiation therapy oncology group prostate cancer trials. , 1999, The Journal of urology.
[124] A. Berardelli,et al. Acute dystonic reaction to ecstasy , 1995, Movement disorders : official journal of the Movement Disorder Society.
[125] F. Schifano,et al. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. , 1998, Drug and alcohol dependence.
[126] T. Wilt,et al. Screening for prostate cancer: A Cochrane systematic review , 2007, Cancer Causes & Control.
[127] L. Holmberg,et al. Quality of life after radical prostatectomy or watchful waiting. , 2002, The New England journal of medicine.
[128] D. Dearnaley,et al. Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).
[129] Alberto M Marchevsky,et al. Evidence-based medicine, medical decision analysis, and pathology. , 2004, Human pathology.
[130] G. Murphy,et al. Purification of a human prostate specific antigen. , 1979, Investigative urology.
[131] E. Turillazzi,et al. Adam (MDMA) and Eve (MDEA) misuse: an immunohistochemical study on three fatal cases. , 1999, Forensic science international.
[132] K. Boone,et al. Neuropsychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy) in Recreational Users , 2003, The Clinical neuropsychologist.
[133] R. Ali,et al. The health effects of ecstasy: a literature review. , 2002, Drug and alcohol review.
[134] J. Fisk,et al. Information processing speed in ecstasy (MDMA) users , 2007, Human psychopharmacology.
[135] Gender Differences Among MDMA Users on Psychological and Drug History Variables , 2005 .
[136] J. Fisk,et al. The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory , 2005, Psychopharmacology.
[137] C. Jurado,et al. Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. , 2003, Forensic science international.
[138] J. van Limbeek,et al. Prognostic factors for ambulation and activities of daily living in the subacute phase after stroke. A systematic review of the literature , 2003, Clinical rehabilitation.
[139] V. Williams,et al. Ecstasy intoxication: appreciation of complications and the role of dantrolene , 1993, Anaesthesia.
[140] Richard D Riley,et al. Evidence-Based Assessment and Application of Prognostic Markers: The Long Way from Single Studies to Meta-Analysis , 2006 .
[141] M. Dennis,et al. Systematic Review of Prognostic Models in Patients with Acute Stroke , 2001, Cerebrovascular Diseases.
[142] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[143] Johan Duflou,et al. Aortic dissection after ingestion of "ecstasy" (MDMA). , 2000, The American journal of forensic medicine and pathology.
[144] S. Nimmo,et al. Drug‐induced hyperthermia , 1993, Anaesthesia.
[145] G. Martinotti,et al. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002 , 2003, Human psychopharmacology.
[146] J. Auer,et al. Subarachnoid haemorrhage with "Ecstasy" abuse in a young adult , 2002, Neurological Sciences.
[147] F. Hamdy,et al. Prognostic value of serum markers for prostate cancer , 2005, Scandinavian journal of urology and nephrology. Supplementum.
[148] J W Moul,et al. Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. , 2001, Urology.
[149] Ming-Hui Chen,et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.
[150] W. G. Cochran. The combination of estimates from different experiments. , 1954 .
[151] J. Gill,et al. Ecstasy (MDMA) deaths in New York City: a case series and review of the literature. , 2002, Journal of forensic sciences.
[152] H. Curran,et al. Neurocognitive function in current and ex-users of ecstasy in comparison to both matched polydrug-using controls and drug-naïve controls , 2007, Psychopharmacology.
[153] R. Dafters. Impulsivity, inhibition and negative priming in ecstasy users. , 2006, Addictive behaviors.
[154] Alex J. Sutton,et al. Methods for Meta-Analysis in Medical Research , 2000 .
[155] J. Cheville,et al. Factors That Influence the Measurement of Prostate Cancer DNA Ploidy and Proliferation in Paraffin Embedded Tissue Evaluated by Flow Cytometry , 2001, Modern Pathology.
[156] R. Eeles,et al. Molecular markers for predicting prostate cancer stage and survival , 2000, BJU international.
[157] W. Jacobs. Fatal Amphetamine-Associated Cardiotoxicity and Its Medicolegal Implications , 2006, The American journal of forensic medicine and pathology.
[158] F. Schifano,et al. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self‐rated aggression and somatic symptoms , 2005, Human psychopharmacology.
[159] M. Luciana,et al. Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use , 2004, Psychological Medicine.
[160] R. Hoffman,et al. The “ecstasy” hangover: Hyponatremia due to 3,4-Methylenedioxymethamphetamine , 2002, Journal of Urban Health.
[161] L. Wartberg,et al. Mental disorders in current and former heavy ecstasy (MDMA) users. , 2005, Addiction.
[162] E. Agaba,et al. Massive intracerebral hematoma and extradural hematoma in amphetamine abuse. , 2002, The American journal of emergency medicine.
[163] B. Schmand,et al. Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report , 2001, Biological Psychiatry.
[164] J. Robinson,et al. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? , 2001, Psychopharmacology.
[165] K. Lu,et al. Biochemical and etiological characteristics of acute hyponatremia in the emergency department. , 2005, The Journal of emergency medicine.
[166] A. Hoznek,et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. , 2003, European urology.
[167] D. Sargent,et al. Comparison of artificial neural networks with other statistical approaches , 2001, Cancer.
[168] D. E. Cox,et al. "ADAM' or "EVE'?--a toxicological conundrum. , 1996, Forensic science international.
[169] D. G. Altman,et al. Review of survival analyses published in cancer journals. , 1995, British Journal of Cancer.
[170] G. Gerra,et al. Long-lasting effects of (±)3,4-methylene-dioxymethamphetamine (Ecstasy) on serotonin system function in humans , 2000, Biological Psychiatry.
[171] Maarten Koeter,et al. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. , 2007, Archives of general psychiatry.
[172] E. Gouzoulis-Mayfrank,et al. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? , 2006, Addiction.
[173] J. Lafitte,et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.
[174] C. Lazarus,et al. Ethanol–MDMA interactions in rats: the importance of interval between repeated treatments in biobehavioral tolerance and sensitization to the combination , 2007, Psychopharmacology.
[175] M. Verbaten. Specific memory deficits in ecstasy users? The results of a meta‐analysis , 2003, Human psychopharmacology.
[176] M. Farré,et al. Pharmacology of MDMA in Humans , 2000, Annals of the New York Academy of Sciences.
[177] A. Rokach,et al. Determinants of Loneliness of Young Adult Drug Users , 2002, The Journal of psychology.
[178] A. Renshaw,et al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. , 2002, International journal of radiation oncology, biology, physics.
[179] R. Schwartz,et al. Accidental ingestion of 'Ecstasy' (3,4-methylenedioxymethylamphetamine). , 1992, Archives of disease in childhood.
[180] T. Randall. Ecstasy-fueled 'rave' parties become dances of death for English youths. , 1992, JAMA.
[181] M. J. Emerson,et al. The Unity and Diversity of Executive Functions and Their Contributions to Complex “Frontal Lobe” Tasks: A Latent Variable Analysis , 2000, Cognitive Psychology.
[182] A. Partin,et al. Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostate-specific antigen. , 1998, Seminars in urologic oncology.
[183] G. Greer,et al. Subjective reports of the effects of MDMA in a clinical setting. , 1986, Journal of psychoactive drugs.
[184] L. Prescott,et al. Hyponatraemia at a rave. , 1997, Postgraduate medical journal.
[185] Galina Pizov,et al. Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.
[186] A. Zaritsky,et al. Transient proximal tubular renal injury following Ecstasy ingestion , 2003, Pediatric Nephrology.
[187] C. McGrath,et al. Oral health sensations associated with illicit drug abuse , 2005, British Dental Journal.
[188] P. Marsden,et al. Amnesic Syndrome and Severe Ataxia Following the Recreational Use of 3,4-methylene-dioxymethamphetamine (MDMA, ‘Ecstacy’) and other Substances , 2001, Neurocase.
[189] J. Tracey,et al. Ecstasy abuse in Ireland. , 1993, Irish medical journal.
[190] Michael Q. Zhang,et al. Profiling alternatively spliced mRNA isoforms for prostate cancer classification , 2006, BMC Bioinformatics.
[191] Y. Sue,et al. Acute Hyponatremia, Seizure, and Rhabdomyolysis After Ecstasy Use , 2002, Journal of toxicology. Clinical toxicology.
[192] David R. Jones,et al. A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. , 2003, Health technology assessment.
[193] F Mosteller,et al. Meta-analysis of multiple outcomes by regression with random effects. , 1998, Statistics in medicine.
[194] Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. , 1988 .
[195] A. Parrott,et al. Auditory verbal learning in drug‐free Ecstasy polydrug users , 2001, Human psychopharmacology.
[196] J. Fisk,et al. Working memory deficits in current and previous users of MDMA ('ecstasy'). , 2000, British journal of psychology.
[197] P. Humphrey,et al. Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives , 2005, Scandinavian journal of urology and nephrology. Supplementum.
[198] B. Trock,et al. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. , 2006, Urology.
[199] Douglas G Altman,et al. Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.
[200] R. Buchert,et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective , 2006, Journal of psychopharmacology.
[201] John F Ward,et al. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. , 2003, The Journal of urology.
[202] James Brierley,et al. The evolving TNM cancer staging system: an essential component of cancer care , 2006, Canadian Medical Association Journal.
[203] A. Bond,et al. Angry cognitive bias, trait aggression and impulsivity in substance users , 2004, Psychopharmacology.
[204] Anthony V D'Amico,et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. , 2007, The Journal of urology.
[205] P. Broadhurst,et al. QT-interval prolongation with Ecstasy. , 1996, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[206] B. Sahakian,et al. Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. , 2005, The American journal of psychiatry.
[207] M. Blute,et al. DNA ploidy and surgically treated prostate cancer. Important independent association with prognosis for patients with prostate carcinoma treated by radical prostatectomy , 1995 .
[208] Steven Piantadosi,et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.
[209] Y C Kim,et al. How to Use an Article About harm. , 2000 .
[210] Hans Garmo,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.
[211] Liesbeth Reneman,et al. A Prospective Cohort Study on Sustained Effects of Low-Dose Ecstasy Use on the Brain in New Ecstasy Users , 2007, Neuropsychopharmacology.
[212] B. Portmann,et al. Acute liver damage and ecstasy ingestion. , 1996, Gut.
[213] R. Holden,et al. Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA) , 1996, The Lancet.
[214] D J Hutchon,et al. Publishing raw data and real time statistical analysis on e-journals , 2001, BMJ : British Medical Journal.
[215] A. Parrott,et al. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance , 1998, Psychopharmacology.
[216] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[217] S. Gore. Fatal uncertainty: death-rate from use of ecstasy or heroin , 1999, The Lancet.
[218] E. Small,et al. Bloodborne biomolecular markers in prostate cancer development and progression , 2002, Nature Reviews Cancer.
[219] J. Blasko,et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. , 2001, Urology.
[220] D. Chowdhury,et al. Atrial fibrillation in an adolescent--the agony of ecstasy. , 2003, Pediatric emergency care.
[221] S. Sharp,et al. Explaining heterogeneity in meta-analysis: a comparison of methods. , 1999 .
[222] L. Webb,et al. Review of deaths related to taking ecstasy, England and Wales, 1997-2000 , 2003, BMJ : British Medical Journal.
[223] J. Dumville,et al. The impact of trial baseline imbalances should be considered in systematic reviews: a methodological case study. , 2007, Journal of clinical epidemiology.
[224] H. Sumnall,et al. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis , 2005, Journal of psychopharmacology.
[225] C. Guillot,et al. Recreational ecstasy use and depression , 2006, Journal of psychopharmacology.
[226] J. Mendelson,et al. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans , 2002, Psychopharmacology.
[227] W. Alexander,et al. Hyponatraemia and seizures after ecstasy use , 1999, Postgraduate medical journal.
[228] R. Dafters. Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”) in rats , 1994, Psychopharmacology.
[229] L. Egevad,et al. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. , 2002, The Journal of urology.
[230] A. Forrest,et al. Pathology of deaths associated with "ecstasy" and "eve" misuse. , 1996, Journal of clinical pathology.
[231] M J Connolly,et al. Cerebral infarction in association with Ecstasy abuse. , 1993, Postgraduate medical journal.
[232] Tatia M.C. Lee,et al. Effect of ecstasy use on neuropsychological function: a study in Hong Kong , 2005, Psychopharmacology.
[233] J. Coore. A Fatal Trip with Ecstasy: A Case of 3,4-Methylene-Dioxymethamphetamine/ 3,4-Methylenedioxy-Amphetamine Toxicity , 1996, Journal of the Royal Society of Medicine.
[234] Richard D Riley,et al. An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown. , 2008, Biostatistics.
[235] C. Smollin,et al. Patterns of ecstasy-associated hyponatremia in California. , 2007, Annals of emergency medicine.
[236] N. Ramsey,et al. Assessment of Cognitive Brain Function in Ecstasy Users and Contributions of Other Drugs of Abuse: Results from an fMRI Study , 2008, Neuropsychopharmacology.
[237] Robert S. Pinals,et al. A double‐blind, placebo‐controlled trial , 1986 .
[238] L. Seiden,et al. Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat , 1998, The Journal of Neuroscience.
[239] M. Karlovsek. Illegal drugs-related fatalities in Slovenia. , 2004, Forensic science international.
[240] C. Sheehan,et al. Prognostic markers inprostate cancer , 2002, Expert review of molecular diagnostics.
[241] R. Verkes,et al. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers , 2006, Journal of psychopharmacology.
[242] D. Chan,et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. , 2001, Urology.
[243] J. Cotorruelo,et al. Ecstasy-induced brain death and acute hepatocellular failure: multiorgan donor and liver transplantation , 2002, Transplantation.
[244] W. van den Brink,et al. Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study , 2006, Journal of psychopharmacology.
[245] R. Riemersma,et al. "Ecstasy" and sudden cardiac death. , 1988, The American journal of forensic medicine and pathology.
[246] H. Curran,et al. The acute and sub-acute effects of 'ecstasy' (MDMA) on processing of facial expressions: preliminary findings. , 2004, Drug and alcohol dependence.
[247] T. Murano,et al. Ecstasy and acute myocardial infarction. , 2004, Annals of Emergency Medicine.
[248] R. Dafters. Chronic ecstasy (MDMA) use is associated with deficits in task-switching but not inhibition or memory updating executive functions. , 2006, Drug and alcohol dependence.
[249] Liesbeth Reneman,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[250] G. Groth-Marnat. Handbook of Psychological Assessment , 2016 .
[251] K. Petersen,et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users , 2003, Psychopharmacology.
[252] J. Maxwell. The response to club drug use , 2003 .
[253] B. Sahakian,et al. Neuropsychological function in ecstasy users: a study controlling for polydrug use , 2006, Psychopharmacology.
[254] L. Bubendorf,et al. Tissue microarray analysis reveals prognostic significance of syndecan‐1 expression in prostate cancer , 2003, The Prostate.
[255] J. A. Henry,et al. Subarachnoid haemorrhage associated with MDMA abuse. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[256] A. Partin,et al. Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease‐free survival among patients with prostate cancer , 1992, Cancer.
[257] Z. Zhang,et al. Computer-assisted diagnostics: application to prostate cancer. , 2001, Molecular urology.
[258] J. Jankovic,et al. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. , 1996, Clinical neuropharmacology.
[259] L. Mair,et al. An association between the regular use of 3,4 methylenedioxy-methamphetamine (ecstasy) and excessive wear of the teeth. , 1998, Addiction.
[260] M. Polkey,et al. Hyponatraemia and catatonic stupor after taking "ecstasy". , 1993, BMJ.
[261] Douglas G. Altman,et al. Systematic reviews in health care : meta-analysis in context , 2008 .
[262] Harry J de Koning,et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.
[263] T. Heffernan,et al. Prospective memory, everyday cognitive failure and central executive function in recreational users of Ecstasy , 2001, Human psychopharmacology.
[264] R. Croft,et al. Chronic MDMA (ecstasy) use, cognition and mood , 2004, Psychopharmacology.
[265] B. Leibovich,et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. , 2006, The Journal of urology.
[266] J. Osredkar,et al. Polydipsia as another mechanism of hyponatremia after 'ecstasy' (3,4 methyldioxymethamphetamine) ingestion. , 2004, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.
[267] R. de la Torre,et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.
[268] R. Bruno,et al. Alcohol Use and Risk Taking Among Regular Ecstasy Users , 2006, Substance use & misuse.
[269] C. Perez,et al. Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[270] R. Freudenmann,et al. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. , 2006, Addiction.
[271] Y. Wong,et al. Subarachnoid hemorrhage and death following coingestion of MDMA with other drugs. , 2004, Journal of the Chinese Medical Association : JCMA.
[272] O. Sheils,et al. Molecular pathology of prostate cancer , 2005, Journal of Clinical Pathology.
[273] K. Davies,et al. Intracerebral haemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations. , 1995, British journal of neurosurgery.
[274] W. A. Soanes,et al. Tissue- and species-specific antigens of normal human prostatic tissue. , 1970, Journal of immunology.
[275] M. Parmar,et al. Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.
[276] I. Olkin,et al. Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .
[277] F. Schifano,et al. Cause and manner of death in drug-related fatality: an analysis of drug-related deaths recorded by coroners in England and Wales in 2000. , 2003, Drug and alcohol dependence.
[278] Richard D Riley,et al. Prognosis research: toward evidence-based results and a Cochrane methods group. , 2007, Journal of clinical epidemiology.
[279] U. McCann,et al. Persistent effects of (+/- )3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. , 1993, Sleep.
[280] M. Cowen,et al. Predicting life expectancy in men with clinically localized prostate cancer. , 2006, The Journal of urology.
[281] M. Mason,et al. The prognostic significance of perineural invasion in prostatic cancer biopsies , 2007, Cancer.
[282] N. Ramsey,et al. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study , 2007, Psychopharmacology.
[283] R. Sansone,et al. Delayed rhabdomyolysis after ecstasy use. , 2001, Mayo Clinic proceedings.
[284] N. Lavies,et al. An overdose of ecstasy , 1992, Anaesthesia.
[285] C. Sheehan,et al. Prognostic factors in prostate cancer. , 2003, American journal of clinical pathology.
[286] R. Pavarin. Substance use and related problems: a study on the abuse of recreational and not recreational drugs in Northern Italy. , 2006, Annali dell'Istituto superiore di sanita.
[287] W. Sakr,et al. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. , 2004, The Journal of urology.
[288] A. Bond,et al. Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users , 2003, Psychopharmacology.
[289] L. Kramer,et al. Successful treatment of refractory cerebral oedema in ecstasy/cocaine-induced fulminant hepatic failure using a new high-efficacy liver detoxification device (FPSA-Prometheus) , 2003, Wiener Klinische Wochenschrift.
[290] J. Oliver,et al. Drug related deaths in the Strathclyde region of Scotland, 1995-1998. , 2001, Forensic science international.
[291] D. Yurgelun-Todd,et al. Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. , 2004, Drug and alcohol dependence.
[292] D. Korf,et al. Long-term ecstasy use and the management of work and relationships , 2006 .
[293] W. Lambert,et al. Amphetamines as Potential Inducers of Fatalities: A review in the district of Ghent from 1976-2004 , 2006, Medicine, science, and the law.
[294] E. Hund,et al. Neuroleptic malignant syndrome following tricyclic antidepressant overdose. , 1997, Intensive Care Medicine.
[295] M. Kew,et al. Liver damage in heatstroke. , 1970, The American journal of medicine.
[296] I. Bosman,et al. Post-mortem cases involving amphetamine-based drugs in The Netherlands. Comparison with driving under the influence cases. , 2007, Forensic science international.
[297] K. Kalantar-Zadeh,et al. Fatal hyponatremia in a young woman after ecstasy ingestion , 2006, Nature Clinical Practice Nephrology.
[298] T. H. van der Kwast,et al. Should we replace the Gleason score with the amount of high-grade prostate cancer? , 2007, European urology.
[299] P. Kantoff,et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[300] M. Parr,et al. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. , 2002, QJM : monthly journal of the Association of Physicians.
[301] Jill Hayden,et al. Evaluation of the Quality of Prognosis Studies in Systematic Reviews , 2006, Annals of Internal Medicine.
[302] Paul W Dickman,et al. Natural history of early, localized prostate cancer. , 2004, JAMA.
[303] A. Harris,et al. Systematic Review of Multiple Studies of Prognosis: The Feasibility of Obtaining Individual Patient Data , 2007 .
[304] C. Haslam,et al. Patterns of Memory Dysfunction in Current and 2-year Abstinent MDMA Users , 2006, Journal of clinical and experimental neuropsychology.
[305] B. Saltin,et al. Esophageal, rectal, and muscle temperature during exercise. , 1966, Journal of applied physiology.
[306] O. Miró,et al. Análisis de las consultas generadas por el consumo de éxtasis en un servicio de urgencias , 2004 .
[307] B. Leibovich,et al. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. , 2006, The Journal of urology.
[308] G K L Butler,et al. Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use. , 2004, Drug and alcohol dependence.
[309] S. Darvish,et al. Two ecstasy-induced myocardial infarctions during a three month period in a young man. , 2007, Archives of Iranian medicine.
[310] D. Kuban,et al. Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer. , 2003, International journal of radiation oncology, biology, physics.
[311] M. Srougi,et al. Prognostic value of the percentage of positive fragments in biopsies from patients with localized prostate cancer. , 2005, International braz j urol : official journal of the Brazilian Society of Urology.
[312] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[313] Syllogistic reasoning performance in MDMA (Ecstasy) users. , 2005, Experimental and clinical psychopharmacology.
[314] Michael J A Parr,et al. Hyponatraemia and death after “ecstasy” ingestion , 1997, The Medical journal of Australia.
[315] Sten Nilsson,et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens , 2005, Scandinavian journal of urology and nephrology. Supplementum.
[316] M W Kattan,et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[317] K. Laws,et al. Ecstasy (MDMA) and memory function: a meta‐analytic update , 2007, Human psychopharmacology.
[318] K. Dar,et al. MDMA induced hyperthermia: Report of a fatality and review of current therapy , 1996, Intensive Care Medicine.
[319] A. Parrott,et al. Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. , 2004, Addictive behaviors.
[320] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[321] D. Hedley. DNA flow cytometry and breast cancer , 1993, Breast Cancer Research and Treatment.
[322] M. Kattan,et al. Prostate cancer nomograms: an update. , 2006, European urology.
[323] M. Srougi,et al. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy , 2005, BJU international.
[324] M. Kattan,et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.
[325] Michael W Kattan,et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[326] D. Kennedy,et al. MDMA polydrug users show processspecific central executive impairments coupled with impaired social and emotional judgement processes , 2006, Journal of psychopharmacology.
[327] S. Moss,et al. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. , 1997, Health technology assessment.
[328] N. Konishi,et al. E-cadherin and α-, β- and γ-catenin expression in prostate cancers: correlation with tumour invasion , 1999, British Journal of Cancer.
[329] D. Linkens,et al. Application of artificial intelligence to the management of urological cancer. , 2007, The Journal of urology.
[330] S. Elliott. MDMA and MDA concentrations in antemortem and postmortem specimens in fatalities following hospital admission. , 2005, Journal of analytical toxicology.
[331] K. Corcoran,et al. Ecstasy (MDMA) exposure and neuropsychological functioning: A polydrug perspective , 2005, Journal of the International Neuropsychological Society.
[332] F. Vollenweider,et al. No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study , 2001, Journal of clinical psychopharmacology.
[333] L. Mortelmans,et al. Spontaneous pneumomediastinum and myocarditis following Ecstasy use: a case report. , 2005, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.
[334] N. Black,et al. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. , 1998, Journal of epidemiology and community health.
[335] A. Rokach. Loneliness and Drug Use in Young Adults , 2002 .
[336] R. de la Torre,et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. , 1999, The Journal of pharmacology and experimental therapeutics.
[337] E. Gouzoulis-Mayfrank,et al. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[338] J. Balažic,et al. Our experiences with fatal ecstasy abuse (two case reports). , 2005, Forensic science international.
[339] Alexander Gimson,et al. Systematic review and validation of prognostic models in liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[340] T. Tena,et al. Amphetamine derivative related deaths. , 1997, Forensic science international.
[341] R. Mattick,et al. The impact of regular ecstasy use on memory function. , 2002, Addiction.
[342] Louis Potters,et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.
[343] C. Compton,et al. College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. , 2000, Archives of pathology & laboratory medicine.
[344] R. Rogers,et al. Elevated Impulsivity and Impaired Decision-Making in Abstinent Ecstasy (MDMA) Users Compared to Polydrug and Drug-Naïve Controls , 2006, Neuropsychopharmacology.
[345] A. V. von Eschenbach,et al. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation , 1987, Cancer.
[346] K. Zakzanis,et al. The neuropsychology of ecstasy (MDMA) use: a quantitative review , 2007, Human psychopharmacology.
[347] J. O'Callaghan,et al. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat , 1991, Pharmacology Biochemistry and Behavior.
[348] U. McCann,et al. The Effect of Catecholamine Depletion by Alpha-Methyl-Para-Tyrosine on Measures of Cognitive Performance and Sleep in Abstinent MDMA Users , 2007, Neuropsychopharmacology.
[349] S. Gardini,et al. Effects of (±) 3,4-methylene–dioxymethamphetamine (ecstasy) on dopamine system function in humans , 2002, Behavioural Brain Research.
[350] Bostwick Dg,et al. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. , 1999 .
[351] E. Snoey,et al. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. , 1998, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[352] M. Kattan,et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. , 1995, The Journal of urology.
[353] L. Sobin,et al. The process for continuous improvement of the TNM classification , 2004, Cancer.
[354] M W Kattan,et al. A catalog of prostate cancer nomograms. , 2001, The Journal of urology.
[355] C. Sheehan,et al. Morphologic and Molecular Prognostic Markers in Prostate Cancer , 2002, Advances in anatomic pathology.
[356] W. Sakr,et al. Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy , 2004, The Prostate.
[357] E. Gehan,et al. Activation of Signal Transducer and Activator of Transcription-5 in Prostate Cancer Predicts Early Recurrence , 2005, Clinical Cancer Research.
[358] A. Oyefeso,et al. "Saturday night fever": ecstasy related problems in a London accident and emergency department. , 1998, Journal of accident & emergency medicine.
[359] A. Walubo,et al. Fatal multi-organ failure after suicidal overdose with MDMA, `Ecstasy': case report and review of the literature , 1999, Human & experimental toxicology.